Oxycodone/naloxone

Oxycodone/naloxone

Combination of
Oxycodone	Opioid analgesic
Naloxone	Opioid receptor antagonist
Clinical data
Trade names	Targin, Targiniq, Targinact, others
AHFS/Drugs.com	International Drug Names UK Drug Information
License data	US DailyMed: Oxycodone hydrochloride/naloxone hydrochloride
Pregnancy category	AU: C
Routes of administration	By mouth
ATC code	N02AA55 (WHO)
Legal status
Legal status	AU: S8 (Controlled drug) CA: Schedule I UK: POM (Prescription only) US: Schedule II In general: ℞ (Prescription only)
Identifiers
CAS Number	92522-88-8
(verify)

Oxycodone/naloxone, sold under the brand name Targin among others, is a combination pain medication. It is available as modified-release tablets and is taken by mouth.

The oxycodone component is an opioid and is responsible for the pain-relieving effects. Naloxone opposes the effects of opioids but is poorly absorbed into the body when given orally, meaning almost all the dose stays within the gastrointestinal tract and reduces the local side effects from the oxycodone, namely constipation as the naloxone binds to the opioid receptors in the gut, preventing the opioid from attaching. This does not affect its analgesic efficacy compared to Oxycontin. Constipation was significantly relieved in a 2008 study. The drug was released in 2006 in Germany and is available in some other European countries since 2009. In the UK, the 10 mg oxycodone / 5 mg naloxone and 20 mg/10 mg strengths were approved in December 2008, and the 40 mg/20 mg and 5 mg/10 mg strengths in July 2019.

Preliminary evidence suggests that oxycodone/naloxone may be an effective treatment for severe, refractory restless legs syndrome if first-line therapies have not been effective.

Adverse effects